Latest Trends in Acute Myeloid Leukemia (AML) Treatment

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It occurs when the bone marrow, which is responsible for producing blood cells, starts making too many abnormal white blood cells called myeloblasts. These abnormal cells crowd out healthy blood cells, leading to a shortage of red blood cells (which carry oxygen), platelets (which help with blood clotting), and normal white blood cells (which fight infections). AML can make a person feel weak, tired, and more susceptible to infections. The treatment for Acute Myeloid Leukemia (AML) typically involves a combination of therapies, like Chemotherapy, Stem Cell Transplant, Targeted Therapy, Care and Clinical Trials. The Global Acute Myeloid Leukemia (AML) Treatment Market report examines the worldwide market of AML treatment. It includes a detailed analysis and prediction of commercially significant products like targeted therapies, anthracycline drugs, and chemotherapies.

The Acute Myeloid Leukemia (AML) treatment market is expected to grow from $3.8B in 2023 to $6.1B by 2028, at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2028. Growth in this market is fuelled by a worldwide increase in elder populations and an increased prevalence of AML., a type of blood cancer affecting many individuals, worldwide. This market has seen significant growth in recent years due to more effective treatment options, which introduce targeted therapies, immunotherapies and combination therapies that specifically target the genetic mutations and abnormalities in AML cells. These advancements improve treatment outcomes and survival rates for AML patients, driving the demand for these therapies in the market. Elder population, exposure to environmental toxins, and genetic susceptibility factors, led to a notable rise in AML cases, driving the demand for AML treatment options. In 2020, AML treatment was significantly impacted by the COVID-19 pandemic, which led to the shutdown of cancer hospitals and chemotherapy procedures.

Key Companies in the AML Treatment Market

AbbVie is a multinational pharmaceutical company headquartered in North Chicago, Illinois, USA. AbbVie is known for its focus on research and development in the fields of immunology, oncology, neuroscience, virology, and general medicine.

Bayer is a life sciences company with core competencies in the areas of healthcare and agriculture. Bayer’s pharmaceutical division focuses on prescription products, especially for cardiology, women’s health, and specialty therapeutics in oncology, hematology, and ophthalmology. Cell and gene therapy is a focus area for the company, as they have established an independent strategic unit for this.

Bristol-Myers Squibb (BMS) is a specialized biopharmaceutical corporation involved in various aspects of the medical industry. The company primarily concentrates on cancer, cardiovascular diseases, immunology, and fibrosis-related therapeutic projects. The company predominately works in oncology, hematology, immunology, cardiovascular and neuroscience.

Novartis is a multinational pharmaceutical corporation based in Basel, Switzerland that is actively engaged in the development of therapies for AML. The company developed an FLT3 inhibitor called Midostaurin (Rydapt), which is approved for some instances of AML.

Astellas Pharma is a Japanese multinational pharmaceutical company that specializes in the research, development, manufacturing, and marketing of pharmaceutical products. It focuses on several therapeutic areas like Oncology, Immunology, Urology, and Transplantation.

Roche is a Swiss multinational healthcare company, known for its innovative research and development in the field of pharmaceuticals. The company focuses on developing and manufacturing a wide range of medications to treat various diseases, including cancer, neurological disorders, infectious diseases, and more.

Servier Laboratories- Servier Laboratories is a pharmaceutical company that is engaged in the R&D of reference products to treat various diseases, including cardiovascular diseases, cancer, and diabetes. It produces drugs for clinical trials in cardiovascular disease, endocrinology, oncology, rheumatology, venous disease, ENT, and neurosciences.

The Acute Myeloid Leukemia (AML) treatment market has been growing steadily in recent years, due to advancements in medical research and technology, leading to the development of more effective treatments for AML. These treatments often include chemotherapy, targeted therapy, stem cell transplantation, and supportive care. It is dynamic in nature. The projected growth of the BCC Research’s report Global Acute Myeloid Leukemia (AML) Treatment Market should reach from $3.8 billion in 2023 to $6.1 billion by 2028 with the expected compound annual growth rate (CAGR) of 10.0% from 2023 to 2028. Overall, the AML treatment market is evolving to provide more effective and tailored solutions. The market's future looks promising, with the potential for more effective and less toxic therapies that can extend the lives of AML patients.

Learn More and Take Action:

Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.